195 related articles for article (PubMed ID: 33653367)
1. Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers.
Zhang P; Huang Y
J Hematol Oncol; 2021 Mar; 14(1):39. PubMed ID: 33653367
[TBL] [Abstract][Full Text] [Related]
2. Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments.
Wang DX; Long JY; Li RZ; Zhang DL; Liu H; Liu J; Tian JC; Li H; Liu J; Zhao HT; Li T
Mol Cancer; 2024 Jan; 23(1):15. PubMed ID: 38225603
[TBL] [Abstract][Full Text] [Related]
3. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.
Rao RC; Dou Y
Nat Rev Cancer; 2015 Jun; 15(6):334-46. PubMed ID: 25998713
[TBL] [Abstract][Full Text] [Related]
4. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.
Wang J; Xiu J; Baca Y; Battaglin F; Arai H; Kawanishi N; Soni S; Zhang W; Millstein J; Salhia B; Goldberg RM; Philip PA; Seeber A; Hwang JJ; Shields AF; Marshall JL; Astsaturov I; Craig Lockhart A; Gatalica Z; Michael Korn W; Lenz HJ
Oncogene; 2021 Jul; 40(30):4894-4905. PubMed ID: 34163031
[TBL] [Abstract][Full Text] [Related]
5. Correlation of KMT2 family mutations with molecular characteristics and prognosis in colorectal cancer.
Liao C; Huang W; Lin M; Li H; Zhang Z; Zhang X; Chen R; Huang M; Yu P; Zhang S
Int J Biol Markers; 2022 Jun; 37(2):149-157. PubMed ID: 35505597
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.
Poreba E; Lesniewicz K; Durzynska J
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302406
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation by the KMT2 histone H3K4 methyltransferases.
Park K; Kim JA; Kim J
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194545. PubMed ID: 32194213
[TBL] [Abstract][Full Text] [Related]
8. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
9. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
10. Biochemical perspectives on targeting KMT2 methyltransferases in cancer.
Zhai X; Brownell JE
Trends Pharmacol Sci; 2021 Aug; 42(8):688-699. PubMed ID: 34074527
[TBL] [Abstract][Full Text] [Related]
11. The role of KMT2 gene in human tumors.
Zhang ZL; Yu PF; Ling ZQ
Histol Histopathol; 2022 Apr; 37(4):323-334. PubMed ID: 35233758
[TBL] [Abstract][Full Text] [Related]
12. KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors.
Zhang R; Wu HX; Xu M; Xie X
Biomark Res; 2020 Dec; 8(1):71. PubMed ID: 33298164
[TBL] [Abstract][Full Text] [Related]
13. KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions.
Van HT; Xie G; Dong P; Liu Z; Ge K
J Mol Biol; 2024 Apr; 436(7):168453. PubMed ID: 38266981
[TBL] [Abstract][Full Text] [Related]
14. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
15. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
16. Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma.
Kumar A; Kumari N; Rai A; Singh SK; Kakkar N; Prasad R
Gene; 2018 Oct; 674():31-36. PubMed ID: 29944950
[TBL] [Abstract][Full Text] [Related]
17. Crystal Structure of MLL2 Complex Guides the Identification of a Methylation Site on P53 Catalyzed by KMT2 Family Methyltransferases.
Li Y; Zhao L; Tian X; Peng C; Gong F; Chen Y
Structure; 2020 Oct; 28(10):1141-1148.e4. PubMed ID: 32697937
[TBL] [Abstract][Full Text] [Related]
18. Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
Zhang QJ; Luan JC; Song LB; Cong R; Ji CJ; Zhou X; Xia JD; Song NH
Front Immunol; 2021; 12():657575. PubMed ID: 33936087
[TBL] [Abstract][Full Text] [Related]
19. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
20. Histone H3 lysine 4 methyltransferase is required for facultative heterochromatin at specific loci.
Zhu Q; Ramakrishnan M; Park J; Belden WJ
BMC Genomics; 2019 May; 20(1):350. PubMed ID: 31068130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
